Acute promyelocytic leukemia: where did we start, where are we now, and the future
about
Acfs: accurate circRNA identification and quantification from RNA-Seq data.Epigenetic Gene Mutations Impact on Outcome in Acute Myeloid Leukaemia.LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia.Role of Signal Regulatory Protein α in Arsenic Trioxide-induced Promyelocytic Leukemia Cell Apoptosis.The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RARα/STAT1 axis.All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity.Oxidative stress-mediated intrinsic apoptosis in human promyelocytic leukemia HL-60 cells induced by organic arsenicals.Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA.Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancerMetabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.Influences of Realgar-Indigo naturalis, A Traditional Chinese Medicine Formula, on the Main CYP450 Activities in Rats Using a Cocktail Method.Fighting against hematological malignancy in China: from unique system to global impact.Small molecule inhibitors for acute myeloid leukemia: where is the field heading?Frontline treatment of acute myeloid leukemia in adults.IDH mutations in cancer and progress toward development of targeted therapeutics.Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.Notch as a tumour suppressor.Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide.HDAC inhibitors cause site-specific chromatin remodeling at PU.1-bound enhancers in K562 cells.Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.Diptoindonesin G promotes ERK-mediated nuclear translocation of p-STAT1 (Ser727) and cell differentiation in AML cells.All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy.Development of a novel microemulsion for oral absorption enhancement of all-trans retinoic acid.A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.Overexpression of lncRNA NEAT1 mitigates multidrug resistance by inhibiting ABCG2 in leukemiaBlood's 70th anniversary: arsenic--from poison pill to magic bullet.Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist.Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis.Lp16-PSP, a Member of YjgF/YER057c/UK114 Protein Family Induces Apoptosis and p21WAF1/CIP1 Mediated G1 Cell Cycle Arrest in Human Acute Promyelocytic Leukemia (APL) HL-60 Cells.Lentivirus-mediated RNA interference targeting FAMLF-1 inhibits cell growth and enhances cell differentiation of acute myeloid leukemia partially differentiated cells via inhibition of AKT and c-MYC.An Effective Model of the Retinoic Acid Induced HL-60 Differentiation Program.microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment.Emerging Roles of MTG16 in Cell-Fate Control of Hematopoietic Stem Cells and Cancer.Tetrandrine antagonizes acute megakaryoblastic leukaemia growth by forcing autophagy-mediated differentiation.
P2860
Q31147507-7128F1B8-7E38-4917-A920-8F078B0AD3D7Q35949137-71BC2F27-F17C-4374-846D-CCE2A829AB68Q35969759-ECC8E65C-CBCE-4AB4-9BD2-E3AEC3C996B0Q36070904-FA3628D5-A493-4C26-8C99-B253F98D56F9Q36303245-889792D3-68C7-4EB5-A683-AE42D9EA0E77Q36724764-C97084FB-4939-4F0B-A795-3F9FD68B4A5CQ36796264-0C48E418-8FAE-43E6-810D-C35D19780FBBQ36989582-A845C3D5-40D9-4424-8C71-CB77F184E39AQ37075360-3AA444BB-1D5C-4364-A90E-C491B1A029B4Q37105038-CAC9DA62-0577-4F4F-B567-83AF19213743Q37304117-FB7496E1-5084-48C1-9555-EB47E8149626Q37536680-4FBD05F8-3A5F-431C-B506-4F1D8B760A36Q37564804-4FDB5BBB-FB02-4945-AC2C-AF18038F80FCQ37736417-CD8F62DB-EED7-4C1A-A495-C87C26169A88Q38632968-50D420C0-FEC0-4ACA-9F87-D9B640F56D49Q38644520-615E348C-AD8F-48C0-A0ED-3D4BC924915FQ38767583-3D22E07E-7E0D-414A-8713-1C0D390C2A09Q38785528-69FB415D-959B-4C5D-B20C-8F56DA7910D7Q38798789-F32F1E49-D2FC-480C-85F0-CE001290CD97Q38891536-70F70C2F-2848-48FC-AC12-33B69B894BA4Q39116742-ACF319F7-C95A-4FF8-A88F-02B5330891AEQ39323997-AC6E435E-CB45-4CDF-A5A1-DF38FD9F15C0Q40252055-59F583F6-D2AB-4D4C-9733-C8AF49856CCFQ40468248-42B55E6B-1F60-4771-B1A1-3A64362A2D48Q41082461-0AA532F1-CBF0-4831-BA7E-98CC74E3DD16Q41082633-10EC9CAF-E1C7-4D3E-B392-70D350EB1A96Q41182592-76B45AE4-53C3-4AB9-B2DE-DF2D0495E964Q41301833-163ED22F-E19E-49B0-A0C0-9E2311565E89Q41593086-2D810DB4-6D0C-4602-91F6-C8C1D956EE34Q41827476-6A72FD0F-404E-4586-AF3F-402FFEF76AE7Q42910730-20446FE2-A4F1-45B6-941C-6F0C3A276CA1Q46246849-ACC28839-1F7F-44F5-849E-4EE835C0B574Q47095624-DA002001-7FF2-41CA-997B-FA2A9E36E92CQ47107765-8523E8FC-FB99-468F-9CB9-F25B48EE0625Q47117677-5E7E5072-F80D-4950-A450-BC82268AE823Q47161998-66716EC6-26DD-4162-B1F2-8C6EB7066FF5Q47375547-7CB691F7-B600-4C8C-895A-3198224A36E7Q47870805-E2500248-533A-4C34-B178-B8898193FA6CQ48189669-693E8F9B-972E-41EF-89A7-5AA9D6EDA163Q48356099-EB07F7F1-0BC3-40E0-A7A4-BBE42610D7EF
P2860
Acute promyelocytic leukemia: where did we start, where are we now, and the future
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@ast
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@en
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@nl
type
label
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@ast
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@en
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@nl
prefLabel
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@ast
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@en
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@nl
P2093
P2860
P921
P3181
P356
P1433
P1476
Acute promyelocytic leukemia: where did we start, where are we now, and the future
@en
P2093
C C Coombs
M S Tallman
M Tavakkoli
P2860
P2888
P3181
P356
10.1038/BCJ.2015.25
P407
P5008
P577
2015-04-17T00:00:00Z
P6179
1026899959